DON’T MISS THE NEXT BIG BUYOUT — THE ARORA REPORT CELEBRATES 215 BUYOUTS
By Nigam Arora
215 Buyouts — A New Record of Success for Arora Members
Avidity Biosciences (RNA) has received a buyout offer from Novartis (NVS) for approximately $12B. RNA is the 215th Arora Portfolio company to be bought out.
This milestone demonstrates the strength of The Arora Report’s approach.
Neuromuscular Diseases
Avidity Biosciences is developing RNA-targeted therapies using its antibody-oligonucleotide conjugate platform to address serious neuromuscular diseases, including Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy.
Buyout Details
RNA is long from $42. The buyout offer is for $72 per share in cash, roughly a 46% premium to the closing price on Friday. … Please click here or the title below to read more.
October 27, 2025